Scholar Rock Holding (SRRK) Notes Payables (2021 - 2024)
Scholar Rock Holding's quarterly Notes Payables came in at $1.6 million in Q2 2024, down 71.13% quarter-over-quarter from $5.5 million in Q1 2024.
Scholar Rock Holding has reported Notes Payables for 4 years, with the latest figure at $1.6 million in Q2 2024.
- For the quarter ending Q2 2024, Notes Payables changed N/A year-over-year to $1.6 million; the trailing twelve-month figure through Jun 2024 stood at $1.6 million (changed N/A YoY), and the FY2023 full-year result was $1.3 million, changed N/A from the prior year.
- Notes Payables for Q2 2024 stood at $1.6 million, down from $5.5 million in the prior quarter.
- The five-year high for Notes Payables was $11.6 million in Q2 2022, with the low at $805000.0 in Q3 2022.
- Average Notes Payables over 4 years is $4.1 million, with a median of $1.6 million recorded in 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 1.59 Mn |
| Mar 31, 2024 | 5.50 Mn |
| Dec 31, 2023 | 1.33 Mn |
| Sep 30, 2022 | 805,000.00 |
| Jun 30, 2022 | 11.58 Mn |
| Mar 31, 2022 | 6.58 Mn |
| Dec 31, 2021 | 1.58 Mn |